Allogene Therapeutics ALLO Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Returns | |||||
| Return on equity | -53.4%+1.7pp | -55.1%+0.4pp | -55.5%-12.7pp | -42.8%-24.0pp | |
| Return on invested capital | -56.5%+1.6pp | -58%-3.9pp | -54.2%-9.8pp | -44.4%-22.9pp | |
| Efficiency | |||||
| Asset turnover | 0×— | 0×0.0× | 0×0.0× | 0×-0.1× | |
| Liquidity | |||||
| Current ratio | 7.9×-0.6× | 8.5×-3.8× | 12.4×+2.5× | 9.8×0.0× | |
| Leverage | |||||
| Debt-to-equity | 0.3×+0.1× | 0.2×0.0× | 0.2×0.0× | 0.2×+0.1× | |
| Per Share | |||||
| Book value per share | $1.33-38.8% | $2.17-33.6% | $3.26-29.9% | $4.66-31.6% | |
| Valuation | |||||
| Market capitalization | $711.02M+164% | $446.6M-17.3% | $540.17M-40.4% | $907.08M-57.3% | |
| Price / book | 2.5×+1.9× | 1.1×0.0× | 1.1×-0.3× | 1.4×-0.9× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Allogene Therapeutics's ratios come from?
- Every ratio is computed from Allogene Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.